Randomized studies of purine analogue single agent versus combinations as initial treatment for chronic lymphocytic leukemia (CLL).
| Study . | Agent . | No. Pts . | % CR . | % OR . | RD . |
|---|---|---|---|---|---|
| Abbreviations: GCLLSG, German CLL Study Group; Pts, patients; CR, complete remission; OR, overall response; RD, remission duration; mo, months; yr, year; PFS, median progression free survival; CC, cladribine + cyclophosphamide; CMC, cladribine + mitoxantrone + cyclophosphamide; FC, fludarabine + cyclophosphamide; UK LRF, UK Leukemia Research Fund; PALG, Polish Adult Leukemia Group | |||||
| GCLLSG-CLL416 | FC vs | 164 | 24 | 95 | 48 mo (PFS) |
| Fludarabine | 164 | 7 | 83 | 20 mo (PFS) | |
| E299417 | FC vs | 125 | 22 | 70 | 41 mo (PFS) |
| Fludarabine | 121 | 6 | 50 | 18 mo (PFS) | |
| UK LRF CLL418 | FC vs | 176 | 38 | 90 | 62% 3 yr-PFS |
| Fludarabine | 176 | 15 | 77 | 31% 3 yr-PFS | |
| PALG CLL220 | Cladribine vs | 166 | 21 | 77 | 24 mo (PFS) |
| CC | 162 | 29 | 83 | 22 mo (PFS) | |
| CMC | 151 | 36 | 80 | 24 mo (PFS) | |
| Study . | Agent . | No. Pts . | % CR . | % OR . | RD . |
|---|---|---|---|---|---|
| Abbreviations: GCLLSG, German CLL Study Group; Pts, patients; CR, complete remission; OR, overall response; RD, remission duration; mo, months; yr, year; PFS, median progression free survival; CC, cladribine + cyclophosphamide; CMC, cladribine + mitoxantrone + cyclophosphamide; FC, fludarabine + cyclophosphamide; UK LRF, UK Leukemia Research Fund; PALG, Polish Adult Leukemia Group | |||||
| GCLLSG-CLL416 | FC vs | 164 | 24 | 95 | 48 mo (PFS) |
| Fludarabine | 164 | 7 | 83 | 20 mo (PFS) | |
| E299417 | FC vs | 125 | 22 | 70 | 41 mo (PFS) |
| Fludarabine | 121 | 6 | 50 | 18 mo (PFS) | |
| UK LRF CLL418 | FC vs | 176 | 38 | 90 | 62% 3 yr-PFS |
| Fludarabine | 176 | 15 | 77 | 31% 3 yr-PFS | |
| PALG CLL220 | Cladribine vs | 166 | 21 | 77 | 24 mo (PFS) |
| CC | 162 | 29 | 83 | 22 mo (PFS) | |
| CMC | 151 | 36 | 80 | 24 mo (PFS) | |